Antoni Wiedlocha funded by the EEA Poland-Norway grants
Antoni Wiedlocha
The proposal "Novel targeted therapy based on dual warhead conjugates against FGFR dependent cancers", with senior scientist Antoni Wiedlocha at Department of Molecular Cell Biology, Institute for Cancer Research, as Norwegian partner and professor Jacek Otlewski at the University of Wroclaw as Polish parther, has been awarded funding from the EEA Poland-Norway grants under the "Applied Research" programme.
Links:
From the National Centre for Research and Development in Poland:
Published in Level 2 journals, first or last author from Oslo University Hospital.
Fosså SD, Haugnes HS, Dahl AA, Kiserud CE, Fosså A, Skalleberg J, Myklebust TÅ(2023) Adverse Health Outcomes and Global Quality of Life in Long-term Testicular Cancer Survivors: A longitudinal 30-year perspective Ann Oncol(in press) DOI 10.1016/j.annonc.2023.09.3101, PubMed 37739265
Jodal HC, Wieszczy-Szczepanik P, Løberg M(2023) Reply to Zhou et al Gastroenterology(in press) DOI 10.1053/j.gastro.2023.09.022, PubMed 37739088
Clement D, Szabo EK, Krokeide SZ, Wiiger MT, Vincenti M, Palacios D, Chang YT, Grimm C, Patel S, Stenmark H, Brech A, Majhi RK, Malmberg KJ(2023) The Lysosomal Calcium Channel TRPML1 Maintains Mitochondrial Fitness in NK Cells through Interorganelle Cross-Talk J Immunol(in press) DOI 10.4049/jimmunol.2300406, PubMed 37737664